News & Updates
Excerpt from the Press Release: BOSTON, July 29, 2020 /PRNewswire/ — Samus Therapeutics, Inc., a privately held, biopharmaceutical company developing small molecule epichaperome inhibitors , today announced the presentation of safety and pharmacokinetic data from the Company’s recently completed PU-AD healthy volunteer Phase 1 study at the Alzheimer’s Association International Conference (AAIC 2020). PU-AD is Samus’…
Read More
Excerpt from the article: “In late January, when hospitals in the United States confirmed the presence of the novel coronavirus, health workers knew to watch for precisely three symptoms: fever, cough, and shortness of breath. But as the number of infections climbed, the symptom list began to grow. Some patients lost their sense of smell…
Read More
Excerpt from the Article: “San Diego start-up Truvian Sciences has received federal emergency approval for a blood test that detects COVID-19 antibodies in as little as 10 minutes. Called Easy Check, the portable test will be sold by Truvian to health professionals for about $15 and has an accuracy rate in excess of 98 percent,…
Read More
Excerpt from the Press Release: “FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)–Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, today announced positive results from its completed Phase 1 single ascending dose and multiple ascending dose study of TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor,…
Read More
Excerpt from the article: “Inovio’s stock climbed as much as 15% in pre-market trading Thursday after the Montgomery County biopharmaceutical company announced its Covid-19 vaccine candidate was effective in protecting non-human primates from the virus 13 weeks after the last vaccination. The stock was up more than 6% to $20.73 per share at Thursday’s close.…
Read More
Excerpt from the article: “A single-shot vaccine for COVID-19 being developed by a group of scientists, led by Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, has proven successful in tests on primates and could begin phase 3 trials as early as September. The results of the tests on the vaccine, developed at…
Read More
Excerpt from the Press Release: “SAN DIEGO–(BUSINESS WIRE)–Selva Therapeutics, Inc. announced today that the company has raised $3 million in a Series A financing round from private investors. The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a leading oral drug candidate for the treatment of COVID-19, the…
Read More
Excerpt from the Press Release: “WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA® platform, enabling processing of up to 5,000 samples per day. The finger-prick sample collection device allows for…
Read More
From The Scientist comes this exciting new development in clinical research into COVID-19: “Upon seeing pregnant women sick with COVID-19 at a University of Pennsylvania hospital, researchers there wrote trial protocols for blood transfusions to treat the disease that include expecting mothers. As a translational infectious disease researcher at the University of Pennsylvania Perelman School…
Read More
Excerpt from the Press Release: “PRINCETON, NJ / ACCESSWIRE / July 20, 2020 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing innovative targeted biologic drugs with enhanced mono or bispecific mechanisms, announced today that it has completed initial preclinical proof-of-concept work with both GMcSF and IL-18 and with GMcSF and IL-12 in a…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?